Gastric Cancer Clinical Trials in St Louis, Missouri
10 studies are recruiting for gastric cancer in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Washington University, School of Medicine, St Louis, Missouri
- Locations
- 90 in total
- Run by
- Daiichi Sankyo
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- WashU - Siteman Cancer Center, St Louis, Missouri
- Locations
- 26 in total
- Run by
- SystImmune Inc.
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Research Site, St Louis, Missouri
- Locations
- 311 in total
- Run by
- AstraZeneca
-
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Female patients with early onset (<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of premature ovarian failure from radiotherapy. Premature ovarian failu…
- Stage
- Not phased
- Ages
- 18 to 50
- Site
- Washington University School of Medicine, St Louis, Missouri
- Run by
- Washington University School of Medicine
-
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Washington University School of Medicine, St Louis, Missouri
- Locations
- 5 in total
- Run by
- ViroMissile, Inc.
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Washington University School of Medicine at St Louis, St Louis, Missouri
- Locations
- 54 in total
- Run by
- Merus B.V.
-
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Investigative Site #110, St Louis, Missouri
- Locations
- 15 in total
- Run by
- MOMA Therapeutics
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
- Stage
- Phase 1
- Ages
- 18 to 90
- Site
- Saint Louis University, St Louis, Missouri
- Locations
- 11 in total
- Run by
- Perspective Therapeutics
-
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
This is a phase I trial of CA-4948 in combination with FOLFOX/PD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer. During the Dose Escalation portion of the study, different dose levels of CA-4948 in combination with FOLFOX/nivolumab will be evaluated by …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Washington University School of Medicine, St Louis, Missouri
- Run by
- Washington University School of Medicine
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Washington University School of Medicine St. Louis, St Louis, Missouri
- Locations
- 208 in total
- Run by
- Shanghai Henlius Biotech
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.